To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor.
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial / Tuckwell, Katie; Collinson, Neil; Dimonaco, Sophie; Klearman, Micki; Blockmans, Daniel; Brouwer, Elisabeth; Cid, Maria C; Dasgupta, Bhaskar; Rech, Juergen; Salvarani, Carlo; Unizony, Sebastian H; Stone, John H.. - In: SEMINARS IN ARTHRITIS AND RHEUMATISM. - ISSN 1532-866X. - 46:5(2017), pp. 657-664. [10.1016/j.semarthrit.2016.11.002]
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial
SALVARANI, CARLO;
2017
Abstract
To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S004901721630275X-main.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
601.41 kB
Formato
Adobe PDF
|
601.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
